Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 4/20 | 0.50 |
| ▸ | CDK2 | P24941 | 4/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6634331 | 0.93 | CCNA2 (0.49) | CCNA2CDK2CCNA1ALDH1A1KDM4E | |
| SCHEMBL6792645 | 0.91 | CCNA2 (0.54) | CCNA2CDK2CCNA1ALDH1A1KDM4E | |
| SCHEMBL6661004 | 0.80 | CCNA2 (0.59) | CCNA2CDK2CCNA1PTGS2PTGS1 | |
| SCHEMBL6787577 | 0.79 | CCNA2 (0.47) | CCNA2CDK2CCNA1PTGS2PTGS1 | |
| SCHEMBL6660064 | 0.79 | CA9 (0.50) | CCNA2CDK2CCNA1ALDH1A1KDM4E | |
| SCHEMBL5226982 | 0.78 | CCNA2 (0.80) | CCNA2CDK2CCNA1 | |
| SCHEMBL6795570 | 0.77 | CCNA2 (0.59) | CCNA2CDK2CCNA1 | |
| SCHEMBL3603926 | 0.74 | LMNA (0.46) | ALDH1A1KDM4ECYP19A1 | |
| SCHEMBL18082803 | 0.74 | CCNA2 (0.46) | CCNA2CDK2CCNA1ALDH1A1KDM4E | |
| SCHEMBL14558176 | 0.74 | CCNA2 (0.50) | CCNA2CDK2CCNA1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | CCNA2 270/4885CDK2 29/4885CCNA1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.